Published in Am J Pathol on December 17, 2009
High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload. PLoS One (2015) 1.44
MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res (2014) 1.09
Iron deprivation in cancer--potential therapeutic implications. Nutrients (2013) 0.98
Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol (2014) 0.97
Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease. World J Nephrol (2012) 0.92
Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. Protein Cell (2014) 0.91
Intestinal iron homeostasis and colon tumorigenesis. Nutrients (2013) 0.88
Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World J Gastroenterol (2012) 0.84
Chronic administration of 2-acetylaminofluorene alters the cellular iron metabolism in rat liver. Toxicol Sci (2011) 0.78
Altered expression of iron regulatory proteins with aging is associated with transient hepatic iron accumulation after environmental heat stress. Blood Cells Mol Dis (2013) 0.75
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
The antioxidant function of the p53 tumor suppressor. Nat Med (2005) 7.57
Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and endosomes. J Cell Sci (2006) 6.98
Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol (2003) 5.46
Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem (1999) 3.95
Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature (2009) 3.90
MDM2 inhibitors for cancer therapy. Trends Mol Med (2006) 3.88
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res (2006) 3.26
How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer (2008) 3.17
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A (2003) 2.73
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A (2006) 2.36
ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem (2007) 2.31
Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. Science (1999) 2.17
Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst (2008) 2.11
The p53 and Mdm2 families in cancer. Curr Opin Genet Dev (2002) 2.07
Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab (2003) 2.06
Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am J Pathol (2009) 1.87
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene (2006) 1.78
Induction of ferritin synthesis by oxidative stress. Transcriptional and post-transcriptional regulation by expansion of the "free" iron pool. J Biol Chem (1995) 1.65
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene (2009) 1.64
DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle (2006) 1.55
Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene (2005) 1.51
Iron regulatory proteins 1 and 2 in human monocytes, macrophages and duodenum: expression and regulation in hereditary hemochromatosis and iron deficiency. Haematologica (2006) 1.51
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood (2006) 1.49
A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem (2005) 1.47
SPLASH: structural pattern localization analysis by sequential histograms. Bioinformatics (2000) 1.46
The chaperones MPP11 and Hsp70L1 form the mammalian ribosome-associated complex. Proc Natl Acad Sci U S A (2005) 1.43
Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res (2006) 1.42
c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res (2008) 1.40
Dynamics in the p53-Mdm2 ubiquitination pathway. Cell Cycle (2004) 1.33
Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology (2007) 1.31
The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest (2008) 1.26
Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr (2008) 1.25
Modulation of iron transport proteins in human colorectal carcinogenesis. Gut (2006) 1.23
Tumor-associated antigen L6 and the invasion of human lung cancer cells. Clin Cancer Res (2003) 1.21
Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology (2001) 1.21
Growth factor-mediated induction of HDM2 positively regulates hypoxia-inducible factor 1alpha expression. Mol Cell Biol (2004) 1.19
Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer. Oncogene (2004) 1.18
hGTSE-1 expression stimulates cytoplasmic localization of p53. J Biol Chem (2004) 1.18
Analysis of ovarian cancer cell lines using array-based comparative genomic hybridization. J Pathol (2005) 1.17
Inappropriately high iron regulatory protein activity in monocytes of patients with genetic hemochromatosis. Blood (1997) 1.17
Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell (2007) 1.17
Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology (1992) 1.16
Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol (2008) 1.14
Tuning cell cycle regulation with an iron key. Cell Cycle (2007) 1.13
Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin Cancer Res (2008) 1.12
Upregulation of annexin A1 expression by butyrate in human colon adenocarcinoma cells: role of p53, NF-Y, and p38 mitogen-activated protein kinase. Mol Cell Biol (2008) 1.12
Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene (2007) 1.10
Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression. Clin Cancer Res (2009) 1.09
Protein kinase C delta induces transcription of the TP53 tumor suppressor gene by controlling death-promoting factor Btf in the apoptotic response to DNA damage. Mol Cell Biol (2007) 1.08
Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica (2007) 1.06
Nucleocytoplasmic transport of proteins and poly(A)+ RNA in reconstituted Tpr-less nuclei in living mammalian cells. Genes Cells (2002) 1.04
Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology (1995) 1.04
The ubiquitin-proteasome system regulates p53-mediated transcription at p21waf1 promoter. Oncogene (2007) 1.00
Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood (2001) 0.98
Role of MAPK phosphatase-1 (MKP-1) in adipocyte differentiation. J Biol Chem (2004) 0.96
Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest (2008) 0.96
The Siva-1 putative amphipathic helical region (SAH) is sufficient to bind to BCL-XL and sensitize cells to UV radiation induced apoptosis. Apoptosis (2004) 0.96
Expression of stem cell factor (SCF), a KIT ligand, in gastrointestinal stromal tumors (GISTs): a potential marker for tumor proliferation. Pathol Res Pract (2008) 0.95
The multifunctional RNA-binding protein La is required for mouse development and for the establishment of embryonic stem cells. Mol Cell Biol (2006) 0.95
FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53. FEBS Lett (2009) 0.95
Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis (2003) 0.95
Overexpression of connective tissue growth factor WISP-1 in Chinese primary rectal cancer patients. World J Gastroenterol (2007) 0.95
Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology (1994) 0.92
Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res (2009) 0.91
Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem (2008) 0.90
Execution of BMP-4-induced apoptosis by p53-dependent ER dysfunction in myeloma and B-cell hybridoma cells. Oncogene (2006) 0.88
The p53 target protein Wig-1 binds hnRNP A2/B1 and RNA Helicase A via RNA. FEBS Lett (2008) 0.88
ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2. Oncogene (2007) 0.87
Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol (2001) 0.85
Ninjurin1 increases p21 expression and induces cellular senescence in human hepatoma cells. J Hepatol (2004) 0.85
Loss of the von Hippel Lindau tumor suppressor disrupts iron homeostasis in renal carcinoma cells. J Biol Chem (2005) 0.84
Cyclin G: a regulator of the p53-Mdm2 network. Dev Cell (2002) 0.84
Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. Blood Cells Mol Dis (2005) 0.84
Genetic inactivation of the APC gene contributes to the malignant progression of sporadic hepatocellular carcinoma: a case report. Genes Chromosomes Cancer (2006) 0.83
Expression patterns of AMP-deaminase isozymes in human hepatocellular carcinoma (HCC). Mol Cell Biochem (2008) 0.83
Imbalance between cell proliferation and cellular DNA fragmentation in hepatocellular carcinoma. Liver (1999) 0.81
The effect of fatty acid-CoA ligase 4 on the growth of hepatic cancer cells. Cancer Biol Ther (2007) 0.78
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev (2004) 9.28
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology (2008) 4.28
Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem (2005) 4.13
Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology (2014) 3.30
Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2010) 2.95
Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology (2015) 2.81
Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int (2012) 2.47
Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology (2011) 2.36
Isolation and characterization of a stem cell population from adult human liver. Stem Cells (2006) 2.25
Lung stress and strain during mechanical ventilation: any difference between statics and dynamics? Crit Care Med (2013) 2.14
Lung inhomogeneities and time course of ventilator-induced mechanical injuries. Anesthesiology (2015) 2.11
Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev (2004) 2.08
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology (2009) 2.07
Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. J Hepatol (2010) 1.78
Lung stress and strain during mechanical ventilation: any safe threshold? Am J Respir Crit Care Med (2011) 1.77
Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol (2003) 1.74
The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol (2011) 1.73
I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology (2010) 1.70
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology (2011) 1.70
Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol (2010) 1.68
Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin. Blood (2009) 1.66
Differential regulation of iron homeostasis during human macrophage polarized activation. Eur J Immunol (2010) 1.64
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut (2012) 1.62
Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol (2002) 1.62
Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol (2011) 1.59
Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol (2010) 1.59
Iron regulatory proteins 1 and 2 in human monocytes, macrophages and duodenum: expression and regulation in hereditary hemochromatosis and iron deficiency. Haematologica (2006) 1.51
Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors. Hepatology (2010) 1.50
Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study. Intern Emerg Med (2006) 1.41
Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol (2007) 1.41
Iron regulatory proteins: from molecular mechanisms to drug development. Antioxid Redox Signal (2010) 1.35
Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med (2008) 1.33
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology (2012) 1.26
Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology (2002) 1.24
New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun (2008) 1.21
PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol (2013) 1.18
DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. PLoS One (2008) 1.18
Adenosine A2a receptor-mediated, normoxic induction of HIF-1 through PKC and PI-3K-dependent pathways in macrophages. J Leukoc Biol (2007) 1.16
Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des (2013) 1.16
The melanocortin system in control of inflammation. ScientificWorldJournal (2010) 1.14
Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol (2008) 1.14
Role of HIF-1 and NF-kappaB transcription factors in the modulation of transferrin receptor by inflammatory and anti-inflammatory signals. J Biol Chem (2008) 1.13
Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods Enzymol (2004) 1.12
The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol (2011) 1.09
A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol (2012) 1.08
Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. Dig Liver Dis (2010) 1.08
Natural history of juvenile haemochromatosis. Br J Haematol (2002) 1.07
Mechanical Power and Development of Ventilator-induced Lung Injury. Anesthesiology (2016) 1.06
Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica (2007) 1.06
Kupffer cells and macrophages are not required for hepatic hepcidin activation during iron overload. Hepatology (2005) 1.06
Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes (2008) 1.05
Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol (2010) 1.05
Detrimental consequences of brain injury on peripheral cells. Brain Behav Immun (2009) 1.05
The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterol (2012) 1.00
An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovasc Toxicol (2007) 1.00
Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin. J Biol Chem (2004) 0.98
The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease? Semin Immunopathol (2009) 0.96
Iron levels in polarized macrophages: regulation of immunity and autoimmunity. Autoimmun Rev (2012) 0.96
Dietary iron overload induces visceral adipose tissue insulin resistance. Am J Pathol (2013) 0.96
Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. Hepatology (2006) 0.95
Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70. FASEB J (2004) 0.94